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Abstract Pharmacological inhibition of VEGF-A has
proven to be effective in inhibiting angiogenesis and
vascular leak associated with cancers and various eye dis-
eases. However, little information is currently available on
the binding kinetics and relative biological activity of various
VEGF inhibitors. Therefore, we have evaluated the binding
kinetics of two anti-VEGF antibodies, ranibizumab and
bevacizumab, and VEGF Trap (also known as aflibercept),
a novel type of soluble decoy receptor, with substantially
higher affinity than conventional soluble VEGF receptors.
VEGF Trap bound to all isoforms of human VEGF-A
tested with subpicomolar affinity. Ranibizumab and bev-
acizumab also bound human VEGF-A, but with markedly
lower affinity. The association rate for VEGF Trap binding
to VEGF-A was orders of magnitude faster than that
measured for bevacizumab and ranibizumab. Similarly, in
cell-based bioassays, VEGF Trap inhibited the activation
of VEGFR1 and VEGFR2, as well as VEGF-A induced
calcium mobilization and migration in human endothelial
cells more potently than ranibizumab or bevacizumab.
Only VEGF Trap bound human PlGF and VEGF-B, and
inhibited VEGFR1 activation and HUVEC migration
induced by PlGF. These data differentiate VEGF Trap from
ranibizumab and bevacizumab in terms of its markedly
higher affinity for VEGF-A, as well as its ability to bind
VEGF-B and PlGF.
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Abbreviations
AMD Age-related macular degeneration
HUVEC Human umbilical vein endothelial cells
VEGF Vascular endothelial growth factor
VEGFR VEGF receptor
PlGF Placental growth factor
Introduction
Angiogenesis is the process by which new vessels are
created from pre-existing vasculature. Abnormal angio-
genesis is a hallmark of diseases such as cancer [1] and the
neovascular or ‘wet’ form of age-related macular degen-
eration (AMD) [2], the leading cause of blindness in the
elderly population [3]. The process is characterized by an
increase in the number of proliferating endothelial and
stromal cells, and altered morphology of the vasculature
[4, 5]. Several proangiogenic factors are consistently
upregulated during diverse forms of pathological angio-
genesis, including two members of the vascular endothelial
growth factor (VEGF) family, VEGF-A and placental
growth factor (PlGF) [6–8]. These factors activate quies-
cent endothelial cells and promote cell proliferation,
migration and vascular permeability [5–9]. As in cancer,
VEGF-A is the major driver of pathological angiogenesis
and vascular leak in wet AMD, as well as in other ocular
vascular diseases, such as diabetic and ischemic
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retinopathies. Moreover, growing evidence suggests that
PlGF synergizes with VEGF-A in promoting vascular
pathology in these diverse conditions [10–16].
In humans and other mammals, the VEGF family of
factors consists of five related glycoproteins, VEGF-A, -B,
-C, -D and PlGF [17, 18]. VEGF-A is the first, and most
well studied member of the VEGF family and is currently a
key target for antiangiogenic therapy [17]. Although
encoded by a single gene, several distinct isoforms of
VEGF-A exist as a result of alternative splicing and/or
proteolytic cleavage. The various VEGF-A isoforms are all
active as dimers, differing principally in their size and their
ability to bind heparin or accessory, non-signaling binding
proteins called neuropilins. For example, VEGF-A165 binds
heparin and neuropilins with low affinity, and is the pre-
dominant isoform expressed in humans. VEGF-A121 is also
expressed at high levels in many tissues and in pathological
conditions, but it lacks the domains that mediate binding to
heparin and neuropilins [17, 18] and is thus freely diffus-
ible. Other isoforms such as VEGF-A189 and VEGF-A206
bind heparin with high affinity and thus accumulate in the
extracellular matrix. Isoforms of VEGF-B and PlGF, which
differ in their capacity to bind heparin and/or neuropilins
are also produced by alternative splicing.
VEGF family ligands bind with high affinity to and
signal through three receptor tyrosine kinases, VEGFR1,
VEGFR2 and VEGFR3 [8, 17–19]. VEGFR2 is expressed
predominantly on vascular endothelial cells. In addition to
being expressed on the vascular endothelium, VEGFR1 is
also expressed by several other cell types including neu-
trophils, monocytes, macrophages, mural cells, and endo-
thelial progenitor cells. Although VEGFR1 has a higher
affinity for VEGF-A than does VEGFR2, in endothelial
cells VEGFR1 exhibits only weak tyrosine phosphorylation
when activated by VEGF-A induced dimerization. Thus,
the effects of all isoforms of VEGF-A on the vascular
endothelium are thought to be mediated primarily through
activation of VEGFR2. PlGF and VEGF-B bind only to
VEGFR1, and in further contrast to VEGF-A, neither PlGF
nor VEGF-B are essential for normal vascular development
or physiological angiogenesis in the adult. However, like
VEGF-A, both PlGF and VEGF-B have been implicated in
pathological vascular remodeling [8, 11, 18]. The remain-
ing VEGF family members, VEGF-C and VEGF-D, bind
with high affinity to VEGFR3. VEGFR3 is found primarily
on lymphatic endothelial cells in the adult. Consequently,
VEGF-C and VEGF-D are involved primarily in the
regulation of lymphangiogenesis [19], although VEGFR3
signaling is also thought to be important for both devel-
opmental and tumor angiogenesis [20–22].
The arsenal of VEGF blockers has evolved over time,
with newer generations offering potentially improved anti-
angiogenic activity by increasing their affinity for VEGF-
A, and/or the number of VEGF-isoforms and family
members that they inhibit. Pegaptanib (MacugenTM, Eye-
tech, Inc.) is an aptamer that selectively binds to and
neutralizes VEGF-A165, but not VEGF-A121, and was the
first anti-VEGF therapy approved for the treatment of wet
AMD [23, 24]. Bevacizumab (Avastin, Genentech, Inc.)
is a recombinant, humanized monoclonal antibody that
binds all isoforms of VEGF-A, and has been approved for
the treatment of metastatic colorectal cancer, non-small-
cell lung cancer, and glioblastoma multiforme [1, 25].
Ranibizumab (Lucentis, Genentech, Inc.) was developed
specifically for intravitreal administration to treat vascular
eye diseases, notably the wet or neovascular form of AMD
[26, 27]. Ranibizumab is an affinity-matured antigen-
binding fragment (Fab) derived from bevacizumab, and
thus has a higher affinity for VEGF-A relative to that of the
parental bevacizumab Fab molecule (Fab-12) [28]. Rani-
bizumab was developed as a Fab because the smaller size
was thought to enhance its diffusion from the vitreous into
the retina and choroid, relative to full-length antibodies
[26]. Being an antibody Fab fragment, each ranibizumab
molecule has one binding site for VEGF (compared to
bevacizumab’s two), such that two molecules of rani-
bizumab are bound by each VEGF dimer. In clinical trials,
pegaptanib was shown to have a modest effect in slowing
the rate of vision loss in patients with wet AMD, while
ranibizumab has proven to be highly effective not only in
reducing macular edema and preventing further vision loss,
but also in producing clinically meaningful improvements
in vision in significant numbers of patients [26, 29, 30].
Ranibizumab has been approved by the FDA for the
treatment of wet AMD, while bevacizumab is also
currently used off-label to treat AMD by intravitreal
administration. While the comparative safety and efficacy
of bevacizumab for the treatment of wet AMD have not yet
been definitively established, several large, controlled
clinical trials comparing the relative efficacy of rani-
bizumab and bevacizumab in the wet AMD are in progress
[31, 32].
VEGF Trap (aflibercept, Regeneron Pharmaceuticals,
Inc.) is a novel type of soluble decoy receptor generated
with Trap technology [33], which employs the fusion of
components from multiple endogenous receptors. VEGF
Trap consists of an all human amino-acid sequence and
comprises the second Ig domain of human VEGFR1 and
the third Ig domain of human VEGFR2 expressed as an
inline fusion with the constant region (Fc) of human IgG1
[34]. Like bevacizumab and ranibizumab, VEGF Trap
binds multiple isoforms of VEGF-A [35] but in contrast to
these antibodies the VEGF Trap was designed to also bind
the related VEGFR1 ligands, VEGF-B and PlGF. An
intravenous formulation of VEGF Trap, generically known
as aflibercept, is being developed for use in oncology
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[ZALTRAPTM (aflibercept)]; this formulation is hyperos-
motic and diluted prior to infusion. An alternate formula-
tion of aflibercept, known as VEGF Trap-Eye [EYLEATM
(aflibercept) Injection)], is an ultra-purified and iso-osmotic
drug product that has been developed specifically for
intravitreal injection for use in the treatment of various
ophthalmological conditions.
Although some data on the binding affinities and in vitro
activities of bevacizumab, ranibizumab and VEGF Trap
have been published [28, 34, 36–40], the available data are
incomplete. Moreover, comparison of the currently available
data for these agents across publications is problematic as the
experimental methods, cell lines, and particular conditions
employed differ significantly from study to study. For
example, the equilibrium dissociation constant (KD) of the
Fab fragment of bevacizumab (Fab-12) for VEGF-A has
been variously reported as 1.8 and 20 nM, as determined by
surface plasmon resonance (SPR) technology (Biacore)
[28, 36], while the binding characteristics of the full bivalent
bevacizumab molecule have not been reported. Thus, the
goal of the present work was to assess the binding properties
and in vitro activity of VEGF Trap, ranibizumab and bev-
acizumab under identical experimental conditions.
The results of these experiments show that VEGF Trap
binds to VEGF-A with higher affinity and a faster association
rate than ranibizumab or bevacizumab, and that VEGF Trap
has the unique ability to additionally bind VEGF-B and
PlGF. Consistent with its higher affinity for VEGF-A and
faster association rate, VEGF Trap demonstrates increased
potency relative to ranibizumab and bevacizumab in block-
ing VEGF-A induced activation of VEGFR1 and VEGFR2
in cell-based assays, and also in blocking VEGF-mediated
calcium mobilization and migration in human endothelial
cells. Finally, the high affinity binding of VEGF Trap to
PlGF is borne out by the finding that only VEGF Trap can
markedly inhibit VEGFR1 activation and endothelial cell
migration induced by PlGF.
Materials and methods
VEGF reagents
Human VEGF-A121, human PlGF-1, human VEGF-C,
human VEGF-D, murine VEGF-A164, murine VEGF-A120,
murine PlGF-2, rat VEGF-A164, human VEGFR1-hFc,
human VEGFR2-hFc and hVEGFR3-hFc were purchased
from R&D Systems (Minneapolis, MN). VEGF Trap,
rabbit VEGF-A165, human PlGF-2, human VEGF-B(10-108)
and human VEGF-A165 were made at Regeneron Phar-
maceuticals, Inc. (Tarrytown, NY). Bevacizumab and
ranibizumab (Genentech, Inc., South San Francisco, CA)
were purchased.
Surface plasmon resonance (SPR)
SPR experiments were performed on a Biacore 3000
instrument using a dextran-coated (CM5) chip at 25C. The
running buffer was filtered HBS-T (10 mM Hepes,
150 mM NaCl, 3.4 mM EDTA, 0.05% polysorbate 20, pH
7.4). A capture sensor surface was prepared by covalently
immobilizing recombinant Protein A (Pierce, Rockford,
IL) or an anti-human Fab polyclonal antibody (human Fab
capture kit, GE Healthcare, Piscataway, NJ) to the chip
surface using (1-Ethyl-3-[3-dimethylaminopropyl]carbodi-
imide hydrochloride)/N-hydroxysuccinimide (EDC/NHS)
coupling chemistry. Following surface activation, Protein
A or anti-human Fab polyclonal antibody in coupling
buffer (0.1 M acetate buffer, pH 4.5) was injected over the
activated chip surface until a resonance unit (RU) signal of
about 2,000 RU (Protein A) or 1,000 RU (anti-human Fab
polyclonal antibody) was reached. The activated coupled
chip surfaces were then washed and treated with 10 mM
glycine–HCl, pH 1.5, to remove uncoupled residual
proteins.
VEGF Trap, bevacizumab or ranibizumab were diluted
into the running buffer and captured on the coupled Protein
A (VEGF Trap and bevacizumab) or anti-human Fab
polyclonal antibody (ranibizumab) chip surface. Following
the capture step, a range of concentrations of test ligands
(1.0–0.062 nM for VEGF-A ligands, 2.5–0.156 nM for
VEGF-B(10-108) and 5.0–0.078 nM for PlGF ligands) were
individually injected over VEGF inhibitor captured
surfaces. For all ligands, the association rate constant (ka)
was determined from data obtained at multiple test ligand
concentrations. The dissociation rate constant (kd), which is
independent of test ligand concentration, was determined
from the change in VEGF inhibitor-bound test ligand RU
over time (*10–70 min) for PlGF and VEGF-B ligands.
Since the dissociation rate (kd) of VEGF-A family ligands
is too slow to allow for sufficient RU change within ligand
dissociation time periods typically employed, the dissoci-
ation rates for these ligands were measured on a Biacore
2000 instrument using the ‘‘fixed kd’’ procedure as descri-
bed by Drake et al. [41]. This format uses a saturating
concentration of ligand for binding, followed by monitor-
ing the dissociation rate for an extended period of time
(*2–3 h). Specific Biacore kinetic sensorgrams (Online
Resource 1, Figures 1–5) were obtained by a double
referencing procedure as described by Myszka et al. [42].
The data were then processed using Scrubber software
(version 2.0, BioLogic Software) and kinetic analyses
performed using BiaEvaluation (version 4.1, Biacore). The
equilibrium dissociation constant (KD) was calculated from
the ratio of the dissociation rate constant divided by the
association rate constant (KD = kd/ka). Similar studies were
conducted to evaluate the binding kinetics of VEGF-A165
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to the extracellular domains of native VEGFR1 and
VEGFR2 fused to human Fc (Online Resource, Fig. 5) and
several other VEGF family related ligands from multiple
species (Online Resource 1, Table 1). Additional studies
demonstrated no detectable binding of VEGF Trap to
human VEGF-C and human VEGF-D, however a positive
control binding experiment confirmed the ability of VEGF-
C and VEGF-D to associate with VEGFR3 (Online
Resource 1, Fig. 5).
KinExA equilibrium assays
In addition to surface capture kinetic experiments, solution
binding studies were also conducted at room temperature
(25C) using a KinExA 3000 instrument (Sapidyne
Instruments, Boise, ID) to quantify the equilibrium binding
constants of VEGF inhibitors in solution, using varying
concentrations of VEGF-A165,VEGF-A121, hPlGF-2 or
VEGF-B(10-108). Inhibitor-ligand mixtures were equili-
brated at room temperature for 10–96 h. Fifty microgram
of human VEGF-A165 was immobilized onto 75 mg
Azlactone beads, suspended in 1.5 ml PBS and rotated at
4C overnight. The supernatant was removed and the beads
were incubated for another hour at room temperature in
1.0 ml PBS with 10 mg/ml BSA to block nonspecific
binding sites. The blocked beads were washed three times
with PBS, resuspended in 30 ml of PBS, and used imme-
diately. Co-complex mixtures contained: VEGF Trap
(concentration range 1–50 pM) with VEGF-A165 or VEGF-
A121 (concentration range 19.5 fM–100 pM) or hPLGF-2
(concentration range 0.5pM–5 nM) or VEGF–B(10–108)
(concentration range 0.61 pM–1.25 nM): Ranibizumab
(concentration range 50–400 pM) with VEGF-A165 (con-
centration range 0.73 pM–15 nM): Bevacizumab (concen-
tration range 25–50 pM) with VEGF-A165 (concentration
range 0.49 pM–5 nM). Human VEGF-A165 was coupled to
Azlactone beads and was used to capture unbound inhibi-
tor. Equilibrated mixtures were injected through a column
of VEGF-A165-coupled micro-beads in the KinExA system
at a flow rate of 0.25 ml/min. Bead contact time was
\0.5 s, permitting unbound VEGF inhibitors to be
captured by the beads without perturbing the equilibrium
state of the solution. Captured VEGF inhibitors were
quantified with Cy5-conjugated goat polyclonal anti-
human IgG or anti-human F(ab0)2 fragment specific for
light-chain antibody (Jackson ImmunoResearch Laborato-
ries, West Grove, PA). The KD was obtained from non-
linear regression analysis of the data using a one-site
homogeneous binding model contained within the KinExA
software (Version 1.0.3; Sapidyne Instruments) using the
‘standard analysis’ method. The software calculates the KD
and determines the 95% confidence interval by fitting the
data points to a theoretical KD curve (Online Resource 1,
Figures 6 and 7). The 95% confidence interval is given as
KD low and KD high as described by Darling et al. [43].
Cell-based bioassays
VEGFR1/VEGFR2 cell lines and VEGF assay
In order evaluate the ability of VEGF Trap, ranibizumab
and bevacizumab to specifically block ligand-mediated
dimerization and activation of VEGFR1 or VEGFR2, two
separate cell lines expressing these receptors were created.
Two chimeric VEGFR1 receptors were constructed that
incorporated the VEGFR1 extracellular domain (1–756,
Genbank # NP_002010) fused to the transmembrane and
cytoplasmic domain of either IL18Ra (328–541, Genbank
# NP_003846.1) or IL18Rb. 355–549, Genbank
# NP_003844.1). The VEGFR1/IL18Ra chimeric receptor
was cloned into a plasmid with a G418 resistance marker,
while the VEGFR1/IL18Rb chimeric receptor was cloned
into a plasmid with a hygromycin resistance marker. The
chimeric receptors were transfected into an HEK293 cell
line with an integrated NFjB-luciferase-IRES-eGFP
reporter gene using Lipofectamine plus (Invitrogen,
Carlsbad, CA) according to manufacturer’s instructions.
Likewise, similar chimeric receptors incorporating
the VEGFR2 extracellular domain (1–764, Genbank
# NP_002244.1) fused to the transmembrane and cyto-
plasmic domain of either IL18Ra or IL18Rb were con-
structed and transfected into the same HEK293 reporter
cell line. In order to isolate cells for use in a bioassay, the
cells were grown in G418 (Invitrogen, Inc.) and hygro-
mycin (Calbiochem) to ensure the presence of both chi-
meric receptors. Cells underwent further selection by
stimulating the cells with VEGF and then sorting cells
expressing GFP by fluorescence activated cell sorting
(FACS). When the extracellular VEGFR1 or VEGFR2 is
dimerized by binding VEGF, the IL18Ra and b intracel-
lular domains interact and are able to signal through the
NFjB driven luciferase reporter gene.
VEGF and PlGF activation of the VEGFR1 and VEGFR2
cell lines
Cells expressing either VEGFR1 or VEGFR2 were resus-
pended at 1.25 9 105 cells/ml in Optimem (Invitrogen,
Inc.) plus 0.1% fetal calf serum (FCS) and 80 ll was
placed in each well of a 96 well plate (10,000 cells/well).
The cells were incubated overnight at 37C, 5% CO2. The
dose response curve for VEGFR1 activation was deter-
mined by adding 20 ll of VEGF-A165, VEGF-A121 or
PlGF-2 (human or mouse) to the cells at concentrations
ranging from 0.022 pM to 4.0 nM. One well served as the
negative control with no test ligand added. The dose
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response curve for VEGFR2 activation was determined by
adding 20 ll of VEGF-A165, VEGF-A121, or hPlGF-2 to
the cells at the same concentrations used above. Each dose
response curve was done in quadruplicate. After addition of
the VEGF or PlGF, the plates were incubated at 37C and
5% CO2 for 6 h, and then equilibrated to room temperature
for 30 min. An equal volume of One-glo luciferase sub-
strate (Promega, Madison, WI) was added to each well and
the plate was incubated at room temperature for a further
15 min. Plates were read on Victor X instrument and the
values were analyzed by a four-parameter logistic equation
over a 12–point dose response curve (Prism, GraphPad
Software, version 5.03, La Jolla, CA).
VEGF Trap, bevacizumab and ranibizumab were tested
with both the VEGFR1 and VEGFR2 cell lines. VEGF
Trap was added to the cells at concentrations ranging from
0.8 pM to 50 nM and included a control well with buffer.
Bevacizumab and ranibizumab were added to the cells at
concentrations ranging from 8.5 pM to 500 nM and
included a control well. Immediately after addition of
VEGF Trap or the antibodies to the VEGFR1 cell line,
VEGF-A165, VEGF-A121, or hPlGF-2 was added to the
cells at a constant concentration of 20 pM (VEGF) or
40 pM (hPlGF-2). The VEGFR2 cell line was stimulated
with 20 pM VEGF-A165 or 20 pM VEGF-A121. The plates
were incubated at 37C and 5% CO2 for 6 h and then
equilibrated to room temperature for 30 min. An equal
volume of One-glo luciferase substrate (Promega) was
added to each well and the plate was incubated at room
temperature for a further 15 min. Plates were read on
Victor X instrument and the values were analyzed by a
four-parameter logistic equation over a 12-point response
curve (GraphPad Prism). Each inhibition curve was done in
triplicate.
VEGF dependent calcium mobilization in human umbilical
vein endothelial cells (HUVEC)
HUVEC (Vec Technologies, Inc., Rensselaer, NY) were
diluted to 3 9 105 cells/ml in MCDB-131 complete med-
ium (Vec Technologies, Inc.), and 100 ll was added to
each well of a 96 well plate. The plates were incubated
overnight at 37C and 5% CO2. The media was then
removed and the HUVEC loaded with a calcium sensitive
dye, Fluo4 NW (Invitrogen, Inc), in ECB media (BD
Biosciences) with 0.25 mM of probenicid and 0.3% BSA
(80 ll per well). The solution was incubated with the cells
for 30 min at 37C and 5% CO2 followed by another
30 min at room temperature.
To measure the dose response, HUVEC were simulated
with buffer or VEGF-A165 at concentrations ranging from
0.023 pM to 4.0 nM. The cellular response was recorded at
a fluorescence emission wavelength of 575 nm with an
excitation of 515 nm for 6 min, using the FLIPRTETRA
(Molecular Devices, Sunnyvale, CA). Each dose response
curve was done in duplicate.
Inhibition of VEGF-A165 was determined by adding
VEGF Trap at concentrations ranging from 0.17 pM to
10.0 nM and for bevacizumab and ranibizumab at con-
centrations ranging from 8.4 pM to 500 nM. VEGF Trap,
bevacizumab, or ranibizumab were incubated with 20 pM
VEGF-A165 for 10 min and then added to the cells, and the
calcium response recorded as above. The data were ana-
lyzed using the average peak fluorescence at each inhibitor
concentration tested in triplicate.
Cell migration assays
Cell culture
HUVEC, at first passage, were purchased from VEC
Technologies and grown at 37C in a 5% CO2 humidified
incubator, in MCDB-131 complete media. Cells grown to
confluency in 10 cm2 culture dishes, were washed twice
with Hank’s Buffered Saline Solution (HBSS; Mediatech,
Manassas, VA.) without calcium, magnesium or phenol
red, and dissociated with Trypsin/EDTA (Lonza, Walk-
ersville, MD). Cells were then seeded at approximately
2 9 105 cells/dish and typically reached confluency in
3–4 days. Prior to use in cell migration assays, cells were
serum-starved for 5 h in MCDB-131 basal media (MBM;
VEC Technologies) supplemented with 2 mM L-glutamine,
100 U/ml Penicillin, 100 lg/ml Streptomycin, 10 lg/ml
heparin, and 0.1% fetal bovine serum.
HUVEC migration
HUVEC migration was assessed using a modified Boyden
chamber [BD FluoroBlokTM 24-well Biocoat angiogenesis
system: Endothelial cell migration (ECM); 3 lm pore size]
according to the manufacturer’s suggested protocol.
Briefly, serum-starved HUVECs were dissociated using
enzyme-free cell dissociation media (Millipore, Billerica,
MA) and resuspended in MBM to a final concentration of
2–3 9 105 cells/ml. An aliquot of resuspended cells
(250 ll; *50,000 cells/well) was placed in the upper well
of the ECM plate, and MBM (750 ll) with or without
ligand (130 pM human VEGF-A165, 7.1 nM human PLGF-
2, or 3.5 nM mouse PLGF-2), was mixed with VEGF Trap,
bevacizumab, or ranibizumab (inhibitor concentration
range 0.013–13 nM) and placed in the lower well follow-
ing a 1 h incubation of the mixture at room temperature.
The ECM plate was incubated for 18–20 h in a 37C/5%
CO2 incubator to allow cells from the upper well to migrate
through the FluoroBlokTM membrane towards the lower
well. Following migration, cells attached to the underside
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of the FluoroBlokTM membrane were stained with 500 lL
of a 2 lg/mL solution of the fluorescent dye Calcein AM
(Anaspec, Freemont, CA) for 1.5 h in a 37C/5% CO2
incubator. Fluorescence emission was measured at 580 nm
with excitation at 485 nm in a Flexstation 3 (Molecular
Devices, Sunnyvale CA) bottom-reading fluorescent plate
reader. Statistical analyses were carried out using a 1-way
ANOVA followed by a Dunnett’s multiple comparison
post hoc test (Prism, GraphPad Software, version 5.03,
La Jolla, CA).
Results
VEGF Trap binds VEGF-A, VEGF-B and PlGF
from multiple species with high affinity
The interaction between VEGF Trap and VEGF family
ligands was measured using SPR-Biacore technology.
Kinetic binding data was generated using an amine-cou-
pled Protein A surface and subsequent VEGF Trap capture
at low density. VEGF Trap bound heparin binding and non-
heparin binding isoforms of human VEGF-A, and PlGF, as
well as VEGF-B(10-108) with high affinity (Table 1 and
Online Resource 1, Table 1). Notably, the equilibrium
dissociation constant (KD) of VEGF Trap for VEGF-A165
(0.490 pM) was significantly lower (tighter binding) than
that of the extracellular domains of dimerized human
VEGFR1 (9.33 pM) or VEGFR2 (88.8 pM) fused inline to
hFc (Table 1 and Online Resource 1, Fig. 5). The above
absolute and relative KD values for VEGFR1-Fc and
VEGFR2-Fc are comparable to those previously reported
for native VEGFR1 and VEGFR2 using cell-based bind-
ings assays [44, 45]. VEGF Trap did not bind human
VEGF-C or human VEGF-D (Online Resource 1, Fig. 5).
The KD values for the interaction between VEGF Trap and
VEGF-A from mouse, rat and rabbit were similar to those
of human and ranged from 0.471 to 0.776 pM. VEGF Trap
also bound human and murine PlGF-2 with a KD of 38.9
and 3.32 pM, respectively (Table 1 and Online Resource 1,
Table 1). In contrast, bevacizumab and ranibizumab are
specific for human and non-human primate VEGF-A, and
do not effectively bind or neutralize rodent VEGF [46–48].
Binding parameters for VEGF Trap, ranibizumab
and bevacizumab interactions with human VEGF-A165
and PlGF-2
While all three VEGF inhibitors bound human VEGF-A165
with high affinity, the KD for VEGF Trap binding of
VEGF-A165 was approximately 100-fold lower (i.e. the
binding affinity was *100-fold tighter) than that for
ranibizumab or bevacizumab (Table 1). Specifically, the
KD value for VEGF Trap was 0.490 pM, while those for
ranibizumab and bevacizumab were 46 and 58 pM,
respectively. The lower KD value for VEGF Trap binding
VEGF-A165 was primarily attributable to a significantly
faster association rate (ka) that was 77- and 256-fold faster
than that for bevacizumab and ranibizumab, respectively
(Table 1). VEGF Trap also bound human PlGF-2 with high
affinity (KD = 38.9 pM), whereas no binding was detected
between ranibizumab or bevacizumab and human PlGF-2
(Table 1). Biacore kinetic sensorgrams analyzed for asso-
ciation and dissociation rate constants are provided in
Online Resource 1, Figures 1–4.
To confirm the surface kinetic data determined using
SPR-Biacore, the binding interactions between soluble
VEGF Trap, bevacizumab or ranibizumab and human
VEGF-A165 were also compared in solution equilibrium
assays using KinExA methodology. As shown in Table 2
and Online Resource 1, Figures 6 and 7, the absolute KD
values and 95% confidence interval obtained for the VEGF
inhibitors binding to VEGF-A165, were comparable to those
obtained with SPR-based measurements. Similarly, VEGF
Trap binding affinities for VEGF-A121, VEGF-B(10-108), and
PlGF were also comparable between SPR and solution
based equilibrium assays.
Effects of VEGF Trap, ranibizumab and bevacizumab
on VEGF-A or PlGF-2 induced activation of VEGFR1
To determine the ability of VEGF Trap, ranibizumab and
bevacizumab to block human VEGF-A or PlGF-2 induced
VEGFR1 activation in vitro, a VEGFR1 specific luciferase
assay was developed, which used the human cell line
HEK293 transfected with an NFjB-luciferase reporter
plasmid and human VEGFR1 (Fig. 1). Notably in this
assay, the potency of ranibizumab for blocking 20 pM
VEGF-A121 or VEGF-A165 induced luciferase activity
through VEGFR1 was only slightly greater than that of
bevacizumab. Ranibizumab exhibited IC50 values (50%
inhibitory concentration) of 675 and 1,140 pM, while IC50
values for bevacizumab were 845 and 1,476 pM for
VEGF-A121 or VEGF-A165, respectively. In contrast,
VEGF Trap exhibited a 45–92-fold greater blocking
potency compared to either ranibizumab or bevacizumab,
with IC50 values of 15 and 16 pM for blocking VEGFR1
activation by 20 pM VEGF-A121 or VEGF-A165, respec-
tively (Table 3; Fig. 1). VEGF Trap also blocked luciferase
activity induced by human PLGF-2 (40 pM) or mouse
PlGF-2 (20 pM) with IC50 values of 2.9 nM and 104 pM,
respectively. In contrast, neither bevacizumab nor rani-
bizumab showed ability to block human or mouse PlGF-2
under these experimental conditions.
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Effects of VEGF Trap, ranibizumab and bevacizumab
on VEGF-A induced activation of VEGFR2
To determine the ability of VEGF Trap, ranibizumab and
bevacizumab to block VEGFR2 activation in vitro, a
VEGFR2 specific luciferase assay was developed, which
used the human cell line HEK293 transfected with an
NFjB-luciferase reporter plasmid and human VEGFR2
(Fig. 2). As for VEGFR1, VEGF Trap efficiently blocked
VEGFR2 signaling induced by 20 pM of human VEGF-
A121 or VEGF-A165 (IC50 of 16 and 26 pM, respectively).
VEGF Trap was again markedly more potent in blocking
VEGF-mediated VEGFR2 activation than either rani-
bizumab or bevacizumab (33–51-fold more potent, see
Fig. 2; Table 3). As expected, hPlGF-2 was not able to
activate VEGFR2 in this assay.
The effect of VEGF Trap, ranibizumab
and bevacizumab on VEGF-A165 induced calcium
mobilization in human endothelial cells
The ability of the three VEGF inhibitors to block human
VEGF-A165 induced activation of VEGF receptors was also
tested in human endothelial cells. A VEGF-A165 induced
calcium mobilization assay was developed using HUVEC
[49, 50], which express native VEGFR1 and VEGFR2
(Fig. 3). Interestingly in this assay, bevacizumab was *5-
fold more potent than ranibizumab at blocking VEGF-A165
induced calcium mobilization. Nevertheless, the IC50 for
VEGF Trap was *27-fold lower than that of bevacizumab
and *129-fold lower than ranibizumab, confirming the
greater potency of VEGF Trap for blocking VEGFR1 and
VEGFR2 activation in vitro (Table 3; Fig. 3). The relative
potency of VEGF blockers in this acute assay may reflect
differences in their association rate constants.
The effect of VEGF Trap, bevacizumab
and ranibizumab on HUVEC migration induced
by VEGF165 or PlGF-2
Endothelial cell migration plays a central part in the pro-
cess of angiogenesis and, consistent with its pro-angiogenic
profile, VEGF acts as a chemoattractant for endothelial
cells [51]. To determine the ability of VEGF Trap, rani-
bizumab and bevacizumab to block human VEGF-A165
induced cell migration, HUVEC mobility was assessed in a
modified Boyden chamber assay. None of the VEGF
inhibitors affected basal endothelial cell migration in the
absence of test ligands (data not shown). In the presence of
VEGF-A165 (130 pM), VEGF Trap blocked VEGF-A165
induced cell migration in a dose-dependent manner (Fig. 4).
At a 1:1 molar ratio of VEGF Trap and VEGF-A165, cell
migration was reduced by approximately 90%. Ranibizumab
and bevacizumab also inhibited cell migration in a dose–
dependent manner (Fig. 4) but were less potent than VEGF
Trap, requiring a 10- to 100-fold greater molar concentration
of inhibitor to produce an equivalent level of inhibition of
cell migration due to VEGF-A165 activation.
PlGF also acts as a chemoattractant for endothelial cells
through VEGFR1 [52]. Again, the modified Boyden
chamber assay was used to test the ability of the VEGF
inhibitors to block HUVEC migration stimulated by human
PlGF-2. As shown in Fig. 4 (inset), a 100-fold excess of
VEGF Trap blocked cell migration induced by human
Table 1 Kinetic binding parameters for VEGF Trap, ranibizumab













VEGF Trapa VEGF-A121 375.0 (5.0) 1.35 (.02) 0.360
VEGF Trapa VEGF-A165 410.0 (10.0) 2.01 (.01) 0.490
Ranibizumabb VEGF-A165 1.6 (0.003) 0.73 (.005) 46
Bevacizumaba VEGF-A165 5.3 (0.01) 3.10 (.02) 58
hVEGFR1-Fca VEGF-A165 300.0 (20.0) 28.0 (1.0) 9.33
hVEGFR2-Fca VEGF-A165 152.0 (5.0) 135 (6.0) 88.8
VEGF Trapa PlGF-2 17.5 (0.06) 6.81 (.03) 38.9
Ranibizumabb PlGF-2 NB NB NB
Bevacizumaba PlGF-2 NB NB NB
VEGF Trapa VEGF-B(10-108) 352.0 (3.0) 6.74 (.09) 1.92
Numbers in parentheses represent the standard error of the kinetic fit
NB No binding under assay conditions used
a VEGF inhibitor captured on a Protein A-coupled sensor chip
b VEGF inhibitor captured on an anti-human Fab polyclonal anti-
body-captured sensor chip
Table 2 Solution binding parameters for VEGF Trap, ranibizumab
and bevacizumab binding to human VEGF family ligands determined
by KinExA equilibrium assays
VEGF inhibitor Ligand Kinexa equilibrium binding
parameters
KD (pM) KD range (pM)
a
VEGF Trap VEGF-A165 0.66 0.36–1.06
Ranibizumab VEGF-A165 20.6 10.9–36.3
Bevacizumab VEGF-A165 35.1 12.2–82.9
VEGF Trap VEGF-A121 0.18 0.08–0.32
VEGF Trap PlGF-2 20.7 13.7–29.3
VEGF Trap VEGF-B(10-108) 17.5 12.9–22.9
a 95% confidence interval
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PlGF-2 (7.1 nM) or mouse PlGF-2 (3.5 nM) by approxi-
mately 80%. In contrast, ranibizumab and bevacizumab did
not inhibit cell migration induced by either human or
mouse PlGF–2.
Discussion
The experiments described herein provide a comprehensive
assessment of the ability of VEGF Trap, ranibizumab and
bevacizumab to bind and block the activity of VEGF family
ligands in vitro, under identical experimental conditions.
The data demonstrate that VEGF Trap binds human VEGF-
A with higher affinity and a significantly faster association
rate, thus neutralizing VEGF-A with greater potency than
ranibizumab or bevacizumab. In addition, the studies show
that VEGF Trap has the unique ability to bind the additional
VEGF family ligands, VEGF-B and PlGF. Moreover, VEGF
Trap also bound VEGF-A and PlGF isoforms from all
mammalian species tested with similar high affinity, while
neither ranibizumab nor bevacizumab efficiently bind and
neutralize mouse or rat VEGF-A [46–48].
Fig. 1 The effects of VEGF Trap, ranibizumab and bevacizumab on
luciferase activation induced by VEGF-A121, VEGF-A165, human
PlGF-2 (hPlGF-2) or mouse PlGF-2 (mPLGF-2) in HEK293/VEG-
FR1 cells. a Dose response curves for VEGF-A121, VEGF-A165 and
hPlGF-2 yielded EC50 values of 13, 17, and 29 pM, respectively.
b Serial dilutions of VEGF Trap (open box), ranibizumab (triangle),
or bevacizumab (closed circle) were added to HEK293/VEGFR1 cells
along with 20 pM of VEGF-A121. c Serial dilutions of VEGF Trap
(open box), ranibizumab (triangle), or bevacizumab (closed circle)
were added to HEK293/VEGFR1 cells along with 20 pM of VEGF-
A165. d Serial dilutions of VEGF Trap (open box), ranibizumab
(triangle), or bevacizumab (closed circle) were added to HEK293/
VEGFR1 cells along with 40 pM of human PlGF-2. e Dose response
curve for mPlGF-2 yielded an EC50 value of 10 pM (f). Serial
dilutions of VEGF Trap were added to HEK293/VEGFR1 cells along
with 20 pM of mPlGF-2. The cells were incubated for 6 h and
OneGlo luciferase substrate was then added to each well. The plates
were read on a luminometer and the data were plotted using a four
parameter curve fit with GraphPad Prism. Each point represents a
replica of 3 wells at each concentration
Table 3 Summary of IC50 values for VEGF Trap, ranibizumab and bevacizumab blocking VEGF-A or PlGF-2 induced activation of VEGFR1
and VEGFR2
VEGF inhibitor VEGFR1 cell line VEGFR2 cell line Ca2? mobilization
in HUVE cells
IC50 at 20 pM
hVEGF-A121
IC50 at 20 pM
hVEGF-A165
IC50 at 40 pM
hPlGF-2
IC50 at 20 pM
mPlGF-2
IC50 at 20 pM
hVEGF-A121
IC50 at 20 pM
hVEGF-A165
IC50 at 20 pM
hVEGF-A165
VEGF Trap 15 pM (2.4) 16 pM (2.2) 2,890 pM (227) 104 pM (23) 16 pM (2.5) 26 pM (11) 2.6 pM (1.2)
Ranibizumab 675 pM (165) 1,140 pM (226) NB NB 576 pM (84) 845 pM (185) 334.9 pM (61.1)
Bevacizumab 854 pM (214) 1,476 pM (288) NB NB 630 pM (66) 1,323 pM (491) 70.8 pM (20.1)
Numbers in parentheses represent standard error of the mean
The IC50 numbers were obtained from at least 3 separate experiments
hVEGF: human VEGF; hPlGF-2: human PlGF-2; mPLGF-2: mouse PlGF-2
NB No blocking activity observed under the assay conditions used
178 Angiogenesis (2012) 15:171–185
123
Several published papers have provided binding affinity
data for ranibizumab’s interactions with human VEGF-A
[28, 36, 37]. However, to date, binding affinity and speci-
ficity data have been provided only for the monovalent Fab
fragment of bevacizumab (Fab-12), and not the full biva-
lent bevacizumab molecule itself. The equilibrium disso-
ciation constant (KD) for Fab-12 has been variously
reported as 1.8 nM [36] or 20 nM [28], indicating an
affinity improvement of ranibizumab over Fab-12 of
10–100-fold. Likewise, ranibizumab has been reported to
be 30–100-fold more potent than Fab-12 in bioassays
measuring VEGF-induced endothelial cell mitogenesis
[26]. However, measuring the kinetic binding parameters
or in vitro activity of the Fab-12 fragment does not take
into account potential avidity interactions of bivalent
antibodies, especially when the binding partner is a dimeric
ligand such as VEGF-A. These types of avidity driven
interactions can significantly increase binding affinity, and
potentially the potency of the bivalent antibody relative to
that of the monovalent antigen binding fragment in cell-
based assays and in vivo.
In the present study, Biacore and KinExA analyses have
demonstrated that the equilibrium dissociation constants for
VEGF Trap binding VEGF-A121 and VEGF-A165, were less
than 1 pM, in close agreement with earlier reports [34]. In
contrast, ranibizumab exhibited a KD of 46 pM for VEGF-
A165. While this represents an approximately 3–4-fold
greater affinity for VEGF-A relative to SPR Biacore values
previously reported for ranibizumab (KD B 140 pM, [28];
B179 pM, [37]), it is nevertheless an *94-fold weaker
binding for VEGF-A165 relative to VEGF Trap (0.490 pM)
(Table 4). Similarly, the KD of soluble VEGF Trap for
VEGF-A165, as determined by KinExA was 0.66 pM, while
that of ranibizumab was 20.6 pM, approximately 30-fold
lower than that of VEGF Trap.
Interestingly, the KD of bevacizumab for VEGF-A165 as
determined by Biacore was 58 pM, markedly lower than
that reported previously for Fab-12 [28, 36] and within
Fig. 2 The effects of VEGF Trap, ranibizumab and bevacizumab on
luciferase activation induced by VEGF-A121 and VEGF-A165 in
HEK293/VEGFR2 cells. a Dose response curves for VEGF-A121 and
VEGF-A165 with EC50 values of 70 and 30 pM, respectively. PlGF-2
was not active in this assay. b Serial dilutions of VEGF Trap (open
box), ranibizumab (triangle) or bevacizumab (closed circle) were
added to HEK293/VEGFR2 cells along with 20 pM of VEGF-A121.
c Serial dilutions of VEGF Trap (open box), ranibizumab (triangle) or
bevacizumab (closed circle) were added to HEK293/VEGFR2 cells
along with 20 pM of VEGF-A165. The cells were incubated for 6 h
and OneGlo luciferase substrate was then added to each well. The
plates were read on a luminometer and the data were plotted using a
four parameter curve fit with GraphPad Prism. Each point represents a
replica of 3 wells at each concentration
Fig. 3 The effects of VEGF Trap, ranibizumab and bevacizumab on
calcium mobilization induced byVEGF-A165 in HUVEC. a A dose–
response curve generated using serial dilutions of VEGF-A165
(4.0 nM–0.023 pM) resulted in an EC50 value of 5 pM. b Serial
dilutions of VEGF Trap (open box), ranibizumab (triangle) or
bevacizumab (closed circle) were added to HUVEC along with
20 pM of VEGF-A165. The VEGF-A165 was preincubated with the
inhibitors for 10 min at 25C. The solution was added to HUVEC
preloaded with fluo-4 and the fluorescence of the well was determined
on a FLIPR instrument. The data were plotted using a four parameter
curve fit with GraphPad Prism. Each point represents duplicate wells
at each concentration
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twofold of the binding affinity of ranibizumab. This was
also the case for soluble equilibrium binding of bev-
acizumab in the Kinexa assay (KD of 35.1 pM for bev-
acizumab and 20.6 pM for ranibizumab), and most likely
reflects avidity interactions of the bivalent, full antibody
molecule. However, like other conventional antibodies that
bind dimeric targets, bevacizumab has the potential to form
higher order complexes with VEGF, which under some
conditions may act as immune complexes [53]. In contrast,
each molecule of VEGF Trap forms an inert 1 to 1 complex
with VEGF, and cannot form higher order complexes [35].
The KD for VEGF Trap binding of VEGF-A docu-
mented in the SPR Biacore and KinExA assays translated
into increased potency relative to ranibizumab and bev-
acizumab in all of the bioassays employed. Specifically,
VEGF Trap was *33–71-fold more potent than rani-
bizumab at inhibiting VEGF-A induced receptor activation
in cell lines expressing either VEGFR1 or VEGR2
(Table 4). Moreover, VEGF Trap was highly effective at
reducing VEGF-A-induced calcium signaling in HUVEC,
where it was *130-fold more potent than ranibizumab
(Table 3). In addition to promoting endothelial cell
proliferation and vascular permeability, VEGF-A is pow-
erful mediator of endothelial cell migration [25]. Consis-
tent with the high potency of VEGF Trap to neutralize
VEGF receptor activation, VEGF Trap was highly effec-
tive at blocking HUVEC migration induced by VEGF-
A165. In agreement with previous reports [38, 54], rani-
bizumab and bevacizumab were also effective at decreas-
ing HUVEC migration, though they were less potent than
VEGF Trap, such that a 10- to 100-fold molar excess of
ranibizumab or bevacizumab was required to completely
block VEGF-induced HUVEC migration, while VEGF
Trap was effective at equimolar concentrations.
Fig. 4 The effects of VEGF Trap, ranibizumab and bevacizumab on
HUVEC migration. a HUVEC were placed in the upper compartment
of the Boyden chamber and allowed to migrate towards basal media
containing 0.1% fetal bovine serum with or without VEGF-A165 or
VEGF-A165 mixed with four concentrations each of VEGF Trap
(circles, solid line), ranibizumab (triangles, dotted line) or bev-
acizumab (squares, dashed line) ranging from 0.013 to 13 nM. The
percentage of total migration (y-axis) was calculated as (FDrug -
FBasal)/(FTotal- FBasal) 9 100; where FTotal is fluorescence in the
presence of VEGF-A165, FBasal is fluorescence in the absence of
VEGF-A165, and FDrug is fluorescence in the presence of VEGF-A165
mixed with drug at a specific molar ratio (x-axis). b HUVEC
migration was assessed in the absence and presence of human PLGF-
2 (hPLGF-2) or mouse PLGF-2 (mPLGF-2) with and without a
100-fold molar excess of VEGF Trap (VGT), ranibizumab (RAN) or
bevacizumab (BEV). Fold migration (y-axis) was calculated as the
ratio F/FBasal; where F is the total fluorescence measured for the
indicated condition (x-axis) and FBasal is the fluorescence in the
absence of either hPLGF-2 or mPLGF-2. Statistical significance:
*P \ 0.05; **P \ 0.01; ns, no significance. Values and error bars
represent the average value and standard error of the mean from at
least three independent experiments with each experiment containing
four biological replicates per condition (total n = 12–16 per condi-
tion) for all conditions tested. AU arbitrary units
Table 4 Relative VEGF binding affinities and potency of VEGFR
signaling blockade





Potency of blocking VEGF (20 pM) mediated signaling
VEGFR1
VEGF-A121 1.0 0.79 45.0
VEGF-A165 1.0 0.77 71.3
VEGFR2
VEGF-A121 1.0 0.91 36.0
VEGF-A165 1.0 0.64 32.5
HUVEC
VEGF-A165 1.0 4.73 128.8
The relative fold differences for the KD and IC50 values for
bevacizumab and VEGF Trap are expressed relative to values for
ranibizumab (set at 1). Higher numbers reflect tighter binding or
increased potency in the indicated assays. Raw values used to cal-
culate relative fold differences were taken from Table 1 and Table 3
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In the present studies, the ability of ranibizumab to
neutralize VEGF-A activity in cell-based assays was only
moderately better than that of bevacizumab. For example,
the IC50 values for inhibition of activation of VEGFR1 and
VEGFR2 by 20 pM VEGF-A were less than twofold lower
for ranibizumab than bevacizumab (Table 3). This corre-
sponded closely to the observed differences in the binding
kinetics of ranibizumab and the full length bivalent
bevacizumab antibody, where the KD of bevacizumab
for VEGF-A was within twofold of that of ranibizumab, as
determined by both Biacore and KinExA assays (Tables 1,
2, 4). Interestingly, bevacizumab was *fivefold more
potent than ranibizumab at neutralizing VEGF-A induced
calcium influx in HUVEC. This finding may reflect the
*threefold faster association rate of bevacizumab
(Table 1), as ka is a critical determinant of potency in
relatively acute cell-based assays.
The above findings stand in contrast to those recently
described by Yu et al. [40]. Specifically, ranibizumab and
VEGF Trap were reported to be equally effective in
blocking endothelial cell proliferation and migration in
HUVEC, while bevacizumab was approximately tenfold
less potent. Evaluation of MAPK phosphorylation, which
reflects activation of intracellular signaling pathways
downstream of the VEGF receptors, showed that all three
agents completely blocked MAPK phosphorylation when
the VEGF inhibitors were pre-incubated with VEGF-A
overnight, before addition to the cells, while VEGF Trap
was more potent than either ranibizumab or bevacizumab
when preincubated with VEGF-A for shorter time periods
(5 and 30 min). The apparent discrepancies with findings
of the present study are likely attributable to the fact that
Yu et al. [40] utilized higher concentrations of exogenous
VEGF-A in all of their cell-based assays, in the range of
0.15–1.25 nM. In other words, the concentration of ligand
was above the KD values for ranibizumab and bev-
acizumab, as well as VEGF Trap (Table 1); under these
assay conditions the IC50 is determined primarily by the
concentration of ligand relative to that of the blocker,
rather than by the binding affinity. Therefore, precise
evaluation of the relative activity of different inhibitors in
bioassays requires utilization of the lowest amount of
VEGF-A practicable, so that the IC50 can reflect differ-
ences in binding affinity and not simply inhibition of
activity at stoichiometric concentrations of inhibitor, which
predominates under conditions where both antibody and
ligand concentrations are well above the KD.
For example, several studies published to date have
reported that ranibizumab and bevacizumab are equally
effective in neutralizing VEGF-induced endothelial cell
proliferation at ‘clinically relevant’ concentrations, i.e.,
those that obtain in the eye shortly following intravitreal
injection [38, 55], which are well above the equilibrium
dissociation constants for both antibodies. Differences in
activity emerge only when lower concentrations of drug are
evaluated, or where acute bioassay readouts reflect differ-
ences in association rate constants. For example, Klettner
et al. [39], reported that at lower concentrations rani-
bizumab more efficiently neutralized VEGF secreted from
retinal-choroidal cultures than did bevacizumab. Costa
et al. [54] also reported that ranibizumab was moderately
more effective at inhibiting endothelial cell proliferation
than bevacizumab, while in an acute assay bevacizumab
more effectively inhibited VEGF-stimulated VEGFR2 and
MAPK phosphorylation in human microvascular endothe-
lial cells.
Binding kinetics and affinity are key determinants of the
biological activity of antibody-like drugs. In addition to
binding affinity, the activity of a drug is also influenced by
the concentration present at the site of target activity,
which is in turn dependent on tissue distribution and
clearance, with larger molecules typically having longer
half-lives. With respect to ocular delivery, it was estimated
that biologically active concentrations of ranibizumab
would be maintained in the vitreous for approximately
4 weeks following intravitreal injections of 0.5 mg
[26, 56]. Indeed, monthly injection of 0.5 mg ranibizumab
has proven to be the most effective regimen for the treat-
ment of neovascular AMD, based on the outcomes of
several phase III clinical trials [29, 57–60], and is the
currently approved regimen for treating this disease. Using
mathematical modeling, and the then available information
on intravitreal clearance and binding affinities, Stewart [61]
predicted that the anti-VEGF bioactivity present in the
vitreous 30 days following intravitreal (IVT) injection of
0.5 mg ranibizumab would be equivalent to that present at
27–38 days following an injection of 1.25 mg bev-
acizumab. More recently, using the same modeling
approach, Stewart and Rosenfeld [62] predicted the intra-
ocular biological activity comparable to that of 0.5 mg
ranibizumab at 30 days post-injection would be maintained
for approximately twice that time following injection of
0.5 mg VEGF Trap, and potentially as long as 12 weeks
following IVT injection of 2 mg VEGF Trap. This sub-
stantial theoretical increase in the relative duration of
VEGF neutralizing activity was driven primarily by the
higher binding affinity of VEGF Trap for VEGF-A com-
pared to ranibizumab, with a lesser contribution of the
predicted longer intravitreal half-life of VEGF Trap (e.g.
4.7 days in rabbits, compared to *2.9 days for
ranibizumab, [63, 64]. Thus, modeling studies suggested
that intravitreal administration of the current clinical doses
of ranibizumab and bevacizumab would result in effective
VEGF-A inhibition of relatively similar duration, while
VEGF Trap might be as efficacious as ranibizumab, but
with less frequent dosing.
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While it remains to be unequivocally determined whe-
ther the durations of bioactivity of these VEGF blockers
predicted by the above modeling studies will be confirmed
by clinical experience, data available to date suggest that
the results of these modeling studies may prove reasonably
accurate. For example, several clinical studies have
investigated alternative strategies to monthly ranibizumab
injection, including quarterly (every 3 months) or pro
renata (PRN) injections following a treatment initiation
phase comprising 3 monthly loading doses. Most large,
well-controlled studies conducted to date have found that
improvements in visual acuity attained during the initiation
phase are lost during the quarterly or PRN maintenance
phases [58–60, 65]. The recent CATT Trial produced the
best results obtained to date using PRN dosing of rani-
bizumab, which was statistically non-inferior to that of
monthly ranibizumab. This may reflect the fact that in the
CATT study patients were followed monthly and rigorous
criteria were established for retreatment [32]. Nevertheless,
the mean improvement in visual acuity attained in CATT
using PRN ranibizumab was 1.6 letters below that of
monthly ranibizumab, at the end of 1 year. Importantly, the
effect of bevacizumab given monthly on visual outcomes
was within 0.4 letters of that obtained with ranibizumab
given monthly. However, bevacizumab administered PRN
failed non-inferiority comparisons to monthly regimens for
both antibodies, despite the fact that it was administered
more frequently than ranibizumab PRN. These findings are
in line with the predictions of modeling studies, as well as
the results of the present report, which indicate that the
binding affinity and in vitro activity of bevacizumab are
moderately less than those of ranibizumab. Several addi-
tional large scale controlled trials are currently in progress
to evaluate the effects of these two antibodies in patients
with neovascular AMD, using both fixed and PRN dosing
schedules [31]. These studies, together with outcomes from
the CATT trial following longer-term treatment, should
provide a clearer picture of the relative clinical activity,
and safety, of ranibizumab and bevacizumab.
Although fewer clinical trials have been conducted to
date with VEGF Trap-Eye, the available data suggest that,
as predicted in modeling studies, the increased affinity of
VEGF Trap for VEGF-A may be reflected in clinical
activity. For example, in a recent double masked phase 2
trial (CLEAR-IT 2) patients with exudative AMD were
randomized to an initiation phase of either a single, or
monthly IVT injections of VEGF Trap for 12 weeks at
doses of either 0.5 or 2 mg. Patients were then switched to
a PRN regimen at their originally assigned doses. Reports
of the 1 year results described maintenance of statistically
significant improvements in vision, retinal thickness and
size of the CNV lesions [66, 67]. Here, patients initially
dosed on a 2.0 mg monthly schedule received, on average,
only 1.6 additional injections during the 40 week PRN
period, and those initially dosed on a 0.5 mg monthly
schedule received, on average, 2.5 injections. More
recently, 1 year results have been reported from two phase
3 clinical trials (VIEW 1 and VIEW 2) in which VEGF
Trap-Eye was dosed monthly at 0.5 or 2.0 mg in patients
with wet AMD, or at 2.0 mg every other month following
an initiation phase of 3 monthly doses. All VEGF Trap-Eye
treatment arms, including the 2.0 mg every other month
treatment regimen, produced improvements in visual acuity
that were equivalent to that obtained in patients dosed with
0.5 mg ranibizumab monthly [68, 69].
The development of ranibizumab has demonstrated that
binding multiple VEGF-A isoforms is of substantial benefit
in the treatment of neovascular AMD, compared to treat-
ment with pegaptanib, which binds only the 165 isoform of
VEGF-A [23, 29, 57, 70–72]. Recent studies have impli-
cated additional VEGF family members, notably PlGF and
VEGF-B, in the pathology of ocular vascular diseases as
well as some cancers [8, 16, 73]. Therefore, a unique
potential advantage of VEGF Trap relative to ranibizumab
and bevacizumab is that it also binds VEGF-B and PlGF
with high affinity. PlGF in particular has been shown to act
in concert with VEGF-A to promote pathological angio-
genesis, vascular leak and inflammation [8, 11, 18, 74], and
like VEGF-A, levels of PlGF are elevated in the eyes of
patients with diverse ocular vascular diseases, including
wet AMD [15, 75]. Furthermore, genetic deletion or
pharmacological inhibition of PlGF has been shown to
inhibit choroidal neovascularization and inflammation, and
to enhance the activity of VEGF-A targeted molecules in
animal models of choroidal neovascularization [13, 16].
More recently, it has been reported that overexpression of
VEGF-B in the murine retina, via adeno-associated virus
gene transfer, also promotes retinal and choroidal neovas-
cularization and blood-retinal barrier breakdown [76].
These studies suggest that targeting PlGF and VEGF-B, in
addition to VEGF-A, could be of added benefit in treating
angiogenic ocular disorders.
Similarly, targeting these additional factors may be
important in the oncology setting. First, these VEGF family
ligands, most notably PlGF, have been implicated in pro-
moting tumor growth [8, 16, 73], therefore inhibiting these
factors, in addition to VEGF-A, may prove therapeutically
beneficial in treating cancer. Bevacizumab, which inhibits
only VEGF-A, is approved for use in various cancer
treatment settings. VEGF Trap, while not currently
approved for use, has also exhibited efficacy in the
oncology setting. Most recently it was reported to have an
overall survival benefit in metastatic colorectal cancer [77].
Changes in the levels of PlGF and other factors have been
observed in patients with metastatic colorectal cancer
treated with bevacizumab, during and following cessation
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of treatment [78, 79], and the authors of both studies
suggested that increases in other pro-angiogenic factors
may be one mechanism underlying the development of
resistance to anti-VEGF therapy. However, further pro-
spective evaluations are needed to confirm these
hypotheses.
In summary, VEGF Trap demonstrated higher binding
affinity for VEGF-A isoforms and greater potency in vitro
than ranibizumab or bevacizumab. These attributes, in
addition to its ability to bind VEGF-B and PlGF, could be
of added benefit in treating various ocular disorders and
cancers.
Acknowledgments The authors thank Douglas MacDonald for
carefully reviewing the data included in this paper and Katherine
Woloshin for assistance in preparing the manuscript and figures. We
also thank our research associates for their assistance in the conduct
of these studies, and our colleagues at Regeneron, Sanofi, and Bayer
HealthCare for their critical reading of this manuscript, and many
helpful comments and suggestions.
Conflict of interest All of the authors are employed by Regeneron
Pharmaceuticals, Inc. and hold equity positions in the company.
Open Access This article is distributed under the terms of the
Creative Commons Attribution License which permits any use, dis-
tribution, and reproduction in any medium, provided the original
author(s) and the source are credited.
References
1. Grothey A, Galanis E (2009) Targeting angiogenesis: progress
with anti-VEGF treatment with large molecules. Nat Rev Clin
Oncol 6:507–518
2. Bressler SB (2009) Introduction: understanding the role of
angiogenesis and antiangiogenic agents in age-related macular
degeneration. Ophthalmology 116:S1–S7
3. Bressler NM (2004) Age-related macular degeneration is the
leading cause of blindness. JAMA 291:1900–1901
4. Folkman J (2007) Angiogenesis: an organizing principle for drug
discovery? Nat Rev Drug 6:273–286
5. Baluk P, Hashizume H, McDonald DM (2005) Cellular abnor-
malities of blood vessels as targets in cancer. Curr Opin Genet
Dev 15:102–111
6. Carmeliet P, Jain RK (2000) Angiogenesis in cancer and other
diseases. Nature 407:249–257
7. Crawford Y, Ferrara N (2009) VEGF inhibition: insights from
preclinical and clinical studies. Cell Tissue Res 335:261–269
8. Cao Y (2009) Positive and negative modulation of angiogenesis
by VEGFR1 ligands. Sci Signal 2:rel
9. Dvorak HF, Nagy JA, Feng D, Brown LF, Dvorak AM (1999)
Vascular permeability factor/vascular endothelial growth factor
and the significance of microvascular hyperpermeability in
angiogenesis. Curr Top Microbiol Immunol 237:97–132
10. Miller JW, Adamis AP, Aiello LP (1997) Vascular endothelial
growth factor in ocular neovascularization and proliferative dia-
betic retinopathy. Diabetes Metab Rev 13:37–50
11. Carmeliet P, Moons L, Luttun A, Vincenti V, Compernolle V, De
Mol M, Wu Y, Bono F, Devy L, Beck H, Scholz D, Acker T,
DiPalma T, Dewerchin M, Noel A, Stalmans I, Barra A, Blacher
S, Vandendriessche T, Ponten A, Eriksson U, Plate KH, Foidart
JM, Schaper W, Charnock-Jones DS, Hicklin DJ, Herbert JM,
Collen D, Persico MG (2001) Synergism between vascular
endothelial growth factor and placental growth factor contributes
to angiogenesis and plasma extravasation in pathological condi-
tions. Nat Med 7:575–583
12. Mitamura Y, Tashimo A, Nakamura Y, Tagawa H, Ohtsuka K,
Mizue Y, Nishihira J (2002) Vitreous levels of placenta growth
factor and vascular endothelial growth factor in patients with
proliferative diabetic retinopathy. Diabetes Care 25:2352
13. Rakic JM, Lambert V, Devy L, Luttun A, Carmeliet P, Claes C,
Nguyen L, Foidart JM, Noel A, Munaut C (2003) Placental
growth factor, a member of the VEGF family, contributes to the
development of choroidal neovascularization. Invest Ophthalmol
Vis Sci 44:3186–3193
14. Schlingemann RO, Witmer AN (2009) Treatment of retinal dis-
eases with VEGF antagonists. Prog Brain Res 175:253–267
15. Witmer AN, Vrensen GF, Van Noorden CJ, Schlingemann RO
(2003) Vascular endothelial growth factors and angiogenesis in
eye disease. Prog Retin Eye Res. 22:1–29
16. Van de Veire S, Stalmans I, Heindryckx F, Oura H, Tijeras-
Raballand A, Schmidt T, Loges S, Albrecht I, Jonckx B,
Vinckier S, Van Steenkiste C, Tugues S, Rolny C, De Mol M,
Dettori D, Hainaud P, Coenegrachts L, Contreres JO, Van
Bergen T, Cuervo H, Xiao WH, Le Henaff C, Buysschaert I,
Kharabi Masouleh B, Geerts A, Schomber T, Bonnin P,
Lambert V, Haustraete J, Zacchigna S, Rakic JM, Jimenez W,
Noel A, Giacca M, Colle I, Foidart JM, Tobelem G, Morales-
Ruiz M, Vilar J, Maxwell P, Vinores SA, Carmeliet G, De-
werchin M, Claesson-Welsh L, Dupuy E, Van Vlierberghe H,
Christofori G, Mazzone M, Detmar M, Collen D, Carmeliet P
(2010) Further pharmacological and genetic evidence for the
efficacy of PlGF inhibition in cancer and eye disease. Cell
141:178–190
17. Ferrara N, Gerber HP, LeCouter J (2003) The biology of VEGF
and its receptors. Nat Med 9:669–676
18. Takahashi H, Shibuya M (2005) The vascular endothelial growth
factor (VEGF)/VEGF receptor system and its role under physi-
ological and pathological conditions. Clin Sci (Lond)
109:227–241
19. Alitalo K, Carmeliet P (2002) Molecular mechanisms of lym-
phangiogenesis in health and disease. Cancer Cell 1:219–227
20. Dumont DJ, Jussila L, Taipale J, Lymboussaki A, Mustonen T,
Pajusola K, Breitman M, Alitalo K (1998) Cardiovascular failure
in mouse embryos deficient in VEGF receptor-3. Science
282:946–949
21. Tammela T, Zarkada G, Wallgard E, Murtoma¨ki A, Suchting S,
Wirzenius M, Waltari M, Hellstro¨m M, Schomber T, Peltonen R,
Freitas C, Duarte A, Isoniemi H, Laakkonen P, Christofori G,
Yla¨-Herttuala S, Shibuya M, Pytowski B, Eichmann A, Betsholtz
C, Alitalo K (2008) Blocking VEGFR-3 suppresses angiogenic
sprouting and vascular network formation. Nature 454:656–
660
22. Tammela T, Zarkada G, Nurmi H, Jakobsson L, Heinolainen K,
Tvorogov D, Zheng W, Franco CA, Murtoma¨ki A, Aranda E,
Miura N, Yla¨-Herttuala S, Fruttiger M, Ma¨kinen T, Eichmann A,
Pollard JW, Gerhardt H, Alitalo K (2011) VEGFR-3 controls tip
to stalk conversion at vessel fusion sites by reinforcing Notch
signalling. Nat Cell Biol 13:1202–1213
23. Gragoudas ES, Adamis AP, Cunningham ET Jr, Feinsod M,
Guyer DR (2004) Pegaptanib for neovascular age-related macular
degeneration. N Engl J Med 351:2805–2816
24. Ng EW, Shima DT, Calias P, Cunningham ET Jr, Guyer DR,
Adamis AP (2006) Pegaptanib, a targeted anti-VEGF aptamer for
ocular vascular disease. Nat Rev Drug Discov 5:123–132
Angiogenesis (2012) 15:171–185 183
123
25. Ferrara N, Hillan KJ, Gerber HP, Novotny W (2004) Discovery
and development of bevacizumab, an anti-VEGF antibody for
treating cancer. Nat Rev Drug Discov 3:391–400
26. Ferrara N, Damico L, Shams N, Lowman H, Kim R (2006)
Development of ranibizumab, an anti-vascular endothelial growth
factor antigen binding fragment, as therapy for neovascular age-
related macular degeneration. Retina 26:859–870
27. Campochiaro PA (2007) Targeted pharmacotherapy of retinal
diseases with ranibizumab. Drugs Today (Barc) 43:529–537
28. Chen Y, Wiesmann C, Fuh G, Li B, Christinger HW, McKay P,
de Vos AM, Lowman HB (1999) Selection and analysis of an
optimized anti-VEGF antibody: crystal structure of an affinity-
matured Fab in complex with antigen. J Mol Biol 293:865–881
29. Rosenfeld PJ, Brown DM, Heier JS, Boyer DS, Kaiser PK, Chung
CY, Kim RY (2006) Ranibizumab for neovascular age-related
macular degeneration. N Engl J Med 355:1419–1431
30. Mone´s J (2010) A review of ranibizumab clinical trial data in
exudative age-related macular degeneration and how to translate
it into daily practice. Ophthalmologica 225:112–119
31. Ziemssen F, Grisanti S, Bartz-Schmidt KU, Spitzer MS (2009)
Off-label use of bevacizumab for the treatment of age-related
macular degeneration: what is the evidence? Drugs Aging
26:295–320
32. The CATT Research Group, Martin DF, Maguire MG, Ying GS,
Grunwald JE, Fine SL, Jaffe GJ (2011) Ranibizumab and bev-
acizumab for neovascular age-realted macular degeneration.
N Engl J Med 364:1897–1908
33. Economides AN, Carpenter LR, Rudge JR, Wong V, Koehler-
Stec EM, Hartnett C, Pyles EA, Xu X, Daly TJ, Young MR,
Fandl JP, Lee F, Carver S, McNay J, Bailey K, Ramakanth S,
Hutabarat R, Huang TT, Radziejewski C, Yancopoulos GD, Stahl
N (2003) Cytokine traps: multi-component, high-affinity blockers
of cytokine action. Nat Med 9:47–52
34. Holash J, Davis S, Papadopoulos N, Croll SD, Ho L, Russell M,
Boland P, Leidich R, Hylton D, Burova E, Ioffe E, Huang T,
Radziejewski C, Bailey K, Fandl JP, Daly T, Wiegand SJ,
Yancopoulos GD, Rudge JS (2002) VEGF-Trap: a VEGF blocker
with potent antitumor effects. Proc Natl Acad Sci USA
99:11393–11398
35. Rudge JS, Holash J, Hylton D, Russell M, Jiang S, Leidich R,
Papadopoulos N, Pyles EA, Torri A, Wiegand SJ, Thurston G,
Stahl N, Yancopoulos GD (2007) VEGF Trap complex formation
measures production rates of VEGF, providing a biomarker for
predicting efficacious angiogenic blockade. Proc Natl Acad Sci
USA 104:18363–18370
36. Presta LG, Chen H, O’Connor SJ, Chisholm V, Meng YG,
Krummen L, Winkler M, Ferrara N (1997) Humanization of an
anti-vascular endothelial growth factor monoclonal antibody for
the therapy of solid tumors and other disorders. Cancer Res
57:4593–4599
37. Lowe J, Araujo J, Yang J, Reich M, Oldendorp A, Shiu V,
Quarmby V, Lowman H, Lien S, Gaudreault J, Maia M (2007)
Ranibizumab inhibits multiple forms of biologically active vas-
cular endothelial growth factor in vitro and in vivo. Exp Eye Res
85:425–430
38. Carneiro A, Falcao M, Pirraco A, Milheiro-Oliveira P, Falcao-
Reis F, Soares R (2009) Comparative effects of bevacizumab,
ranibizumab and pegaptanib at intravitreal dose range on endo-
thelial cells. Exp Eye Res 88:522–527
39. Klettner A, Roider J (2008) Comparison of bevacizumab, rani-
bizumab, and pegaptanib in vitro: efficiency and possible addi-
tional pathways. Invest Ophthalmol Vis Sci 49:4523–4527
40. Yu L, Liang XH, Ferrara N (2011) Comparing protein VEGF
inhibitors: in vitro biological studies. Biochem Biophys Res
Commun 408:276–281
41. Drake AW, Myszka DG, Klakamp SL (2004) Characterizing
high-affinity antigen/antibody complexes by kinetic- and equi-
librium-based methods. Anal Biochem 328:35–43
42. Myszka DG (1999) Improving biosensor analysis. J Mol Recognit
12:279–284
43. Darling RJ, Brault PA (2004) Kinetic exclusion assay technology:
characterization of molecular interactions. Assay Drug Dev
Technol 2:647–657
44. Quinn TP, Peters KG, De Vries C, Ferrara N, Williams LT (1993)
Fetal liver kinase 1 is a receptor for vascular endothelial growth
factor and is selectively expressed in vascular endothelium. Proc
Natl Acad Sci USA 90:7533–7537
45. Waltenberger J, Claesson-Welsh L, Siegbahn A, Shibuya M,
Heldin CH (1994) Different signal transduction properties of
KDR and Flt1, two receptors for vascular endothelial growth
factor. J Biol Chem 269:26988–26995
46. Fuh G, Wu P, Liang WC, Ultsch M, Lee CV, Moffat B, Wies-
mann C (2006) Structure-function studies of two synthetic anti-
vascular endothelial growth factor Fabs and comparison with the
Avastin Fab. J Biol Chem 10;281:6625–6631
47. Yu L, Wu X, Cheng Z, Lee CV, LeCouter J, Campa C, Fuh G,
Lowman H, Ferrara N (2008) Interaction between bevacizumab
and murine VEGF-A: a reassessment. Invest Ophthalmol Vis Sci
49:522–527
48. Lu F, Adelman RA (2009) Are intravitreal bevacizumab and
ranibizumab effective in a rat model of choroidal neovasculari-
zation? Graefes Arch Clin Exp Ophthalmol 247:171–177
49. Meyer RD, Singh A, Majnoun F, Latz C, Lashkari K, Rahimi N
(2004) Substitution of C-terminus of VEGFR-2 with VEGFR-1
promotes VEGFR-1 activation and endothelial cell proliferation.
Oncogene 23:5523–5531
50. Dawson NS, Zawieja DC, Wu MH, Granger HJ (2006) Signaling
pathways mediating VEGF165-induced calcium transients and
membrane depolarization in human endothelial cells. FASEB J
20:991–993
51. Yoshida A, Anand-Apte B, Zetter BR (1996) Differential endo-
thelial migration and proliferation to basic fibroblast growth factor
and vascular endothelial growth factor. Growth Factors 13:57–64
52. Hauser S, Weich HA (1993) A heparin-binding form of placenta
growth factor (PlGF-2) is expressed in human umbilical vein
endothelial cells and in placenta. Growth Factors 9:259–268
53. Meyer T, Robles-Carrillo L, Robson T, Langer F, Desai H,
Davila M, Amaya M, Francis JL, Amirkhosravi A (2009) Bev-
acizumab immune complexes activate platelets and induce
thrombosis in FCGR2A transgenic mice. J Thromb Haemost
7:171–181
54. Costa R, Carneiro A, Rocha A, Pirraco A, Falcao M, Vasques L,
Soares R (2009) Bevacizumab and ranibizumab on microvascular
endothelial cells: a comparative study. J Cell Biochem
108:1410–1417
55. Spitzer MS, Yoeruek E, Sierra A, Wallenfels-Thilo B, Schraer-
meyer U, Spitzer B, Bartz-Schmidt KU, Szurman P (2007)
Comparative antiproliferative and cytotoxic profile of bev-
acizumab (Avastin), pegaptanib (Macugen) and ranibizumab
(Lucentis) on different ocular cells. Graefes Arc Clin Exp Oph-
thalmol 245:1837–1842
56. Gaudreault J, Fei D, Rusit J, Suboc P, Shiu V (2005) Preclinical
pharmacokinetics of Ranibizumab (rhuFabV2) after a single in-
travitreal administration. Invest Ophthalmol Vis Sci 46:726–733
57. Brown DM, Kaiser PK, Michels M, Soubrane G, Heier JS, Kim
RY, Sy JP, Schneider S (2006) Ranibizumab versus verteporfin
for neovascular age-related macular degeneration. N Engl J Med
355:1432–1444
58. Regillo CD, Brown DM, Abraham P, Yue H, Ianchulev T,
Schneider S, Shams N (2008) Randomized, double-masked,
184 Angiogenesis (2012) 15:171–185
123
sham-controlled trial of ranibizumab for neovascular age-related
macular degeneration: PIER Study year 1. Am J Ophthalmol
145:239–248
59. Schmidt-Erfurth U, Eldem B, Guymer R, Korobelnik JF, Sch-
lingemann RO, Axer-Siegel R, Wiedemann P, Simader C, Ge-
kkieva M, Weichselberger A (2011) Efficacy and safety of
monthly versus quarterly ranibizumab treatment in neovascular
age-related macular degeneration the EXCITE study. Ophthal-
mology 118:831–839
60. Holz FG, Amoaku W, Donate J, Guymer RH, Kellner U, Sch-
lingemann RO, Weichselberger A, Staurenghi G (2011) Safety
and efficacy of a flexible dosing regimen of ranibizumab in
neovascular age-related macular degeneration: the SUSTAIN
study. Ophthalmology 118:663–671
61. Stewart MW (2007) Predicted biologic activity of intravitreal
bevacizumab. Retina 27:1196–1200
62. Stewart MW, Rosenfeld PJ (2008) Predicted biological activity of
intravitreal VEGF Trap. Br J Ophthalmol 92:667–668
63. Furfine E, Coppi A, Koehler-Stec E, Zimmer E, Tu W, Struble C.
Pharmacokinetics and ocular tissue penetration of VEGF Trap
after intravitreal injections in rabbits. Invest Opthalmol Vis Sci
47:E-abstract 1430
64. Bakri SJ, Snyder MR, Reid JM, Pulido JS, Ezzat MK, Singh RJ
(2007) Pharmacokinetics of intravitreal ranibizumab (Lucentis).
Ophthalmology 114:2179–2182
65. Boyer DS, Heier JS, Brown DM, Francom SF, Ianchulev T,
Rubio RG (2009) A Phase IIIb study to evaluate the safety of
ranibizumab in subjects with neovascular age-related macular
degeneration. Ophthalmology 116:1731–1739
66. Brown DM, Heier JS, Ciulla T, Benz M, Abraham P, Yancopo-
ulos G, Stahl N, Ingerman A, Vitti R, Berliner AJ, Yang K,
Nguyen QD, CLEAR-IT 2 Investigators (2011) Primary endpoint
results of a phase II study of vascular endothelial growth factor
trap-eye in wet age-related macular degeneration. Ophthalmology
118:1089–1097
67. Heier JS, Boyer D, Nguyen QD, Marcus D, Roth DB, Yanco-
poulos G, Stahl N, Ingerman A, Vitti R, Berliner AJ, Yang K,
Brown DM, CLEAR-IT 2 Investigators (2011) The 1-year results
of CLEAR-IT 2, a phase 2 study of vascular endothelial growth
factor trap-eye dosed as-needed after 12-week fixed dosing.
Ophthalmology 118:1098–1106
68. Nguyen QD, Heier J, Brown D, Ho A, Kaiser P, Vitti R, VIEW 1
Study Group (2011) Randomized, double-masked, active-con-
trolled phase 3 trial of the efficacy and safety of intravitreal
VEGF Trap-eye in Wet AMD: one-year results of the view-1
study. Invest Ophthalmol Vis Sci 52:E-abstract 3073
69. Schmidt-Erfurth U, Chong V, Kirchhof B, Korobelnik JF, Papp
A, Anderesi M, Groetzbach G, Sommerauer B, Sandbrink R,
Ogura Y (2011) Primary results of an international phase III study
using intravitreal VEGF trap-eye compared to ranibizumab in
patients with Wet AMD (VIEW2). Invest Ophthalmol Vis Sci
52:E-abstract 1650
70. VEGF Inhibition Study in Ocular Neovascularization
(V.I.S.I.O.N.) Clinical Trial Group, Chakravarthy U, Adamis AP,
Cunningham ET Jr, Goldbaum M, Guyer DR, Katz B, Patel M
(2006) Year-2 efficacy results of 2 randomized controlled clinical
trials of pegaptanib for neovascular age-related macular degen-
eration. Ophthalmology 113:1508.e1–1508.e25
71. Ciulla TA, Rosenfeld PJ (2009) Antivascular endothelial growth
factor therapy for neovascular age-related macular degeneration.
Curr Opin Ophthalmol 20:158–165
72. Moussa S, Ansari-Shahrezaei S, Smretschnig E, Hagen S, Ste-
indl-Kuscher K, Krebs I, Binder S (2010) Contrast sensitivity
after intravitreal antivascular endothelial growth factor therapy
for myopic choroidal neovascularization. Graefes Arch Clin Exp
Ophthalmol 248:1087–1090
73. Yao J, Wu X, Kasman IM, Vogt T, Phan V, Shibuya M, Ferrara
N, Bais C (2011) Expression of a functional VEGFR-1 in tumor
cells is a major determinant of anti-PlGF antibodies efficacy. Proc
Natl Acad Sci USA 108:11590–11595
74. Luttun A, Tjwa M, Moons L, Wu Y, Angelillo-Scherrer A, Liao
F, Nagy JA, Hooper A, Priller J, De Klerck B, Compernolle V,
Daci E, Bohlen P, Dewerchin M, Herbert JM, Fava R, Matthys P,
Carmeliet G, Collen D, Dvorak HF, Hicklin DJ, Carmeliet P
(2002) Revascularization of ischemic tissues by PlGF treatment,
and inhibition of tumor angiogenesis, arthritis and atherosclerosis
by anti-Flt1. Nat Med 8:831–840
75. Miyamoto N, de Kozak Y, Jeanny JC, Glotin A, Mascarelli F,
Massin P, BenEzra D, Behar-Cohen F (2007) Placental growth
factor-1 and epithelial haemato-retinal barrier breakdown:
potential implication in the pathogenesis of diabetic retinopathy.
Diabetologia 50:461–470
76. Zhong X, Huang H, Shen J, Zacchigna S, Zentilin L, Giacca M,
Vinores SA (2011) Vascular endothelial growth factor-B gene
transfer exacerbates retinal and choroidal neovascularization and
vasopermeability without promoting inflammation. Mol Vis
17:492–507
77. Van Cutsem E, Tabernero J, Lakomy R et al. Intravenous (IV)
aflibercept versus placebo in combination with irinotecan/5-FU
(FOLFIRI) for second-line treatment of metastatic colorectal
cancer (MCRC): Results of a multinational phase III trial
(EFC10262-VELOUR). Ann Oncol 22(supplement 5): v10–v18.
Abstract O-0024
78. Kopetz S, Hoff PM, Morris JS, Wolff RA, Eng C, Glover KY,
Adinin R, Overman MJ, Valero V, Wen S, Lieu C, Yan S, Tran
HT, Ellis LM, Abbruzzese JL, Heymach JV (2010) Phase II trial
of infusional fluorouracil, irinotecan, and bevacizumab for met-
astatic colorectal cancer: efficacy and circulating angiogenic
biomarkers associated with therapeutic resistance. J Clin Oncol
28:453–459
79. Lieu C, Tran H, Jian Z, Mao M, Overman M, Eng C, Morris J,
Ellis L, Heymach J, Kopetz S. The association of alternate VEGF
ligands with resistance to anti-VEGF therapy in metastatic
colorectal cancer (mCRC). J Clin Oncol 29:suppl. abstr 3533
Angiogenesis (2012) 15:171–185 185
123
